Reach Diagnostic

Executive Summary

Reach Diagnostic (Wuhan) Biotech Co., Ltd. is a Chinese in-vitro diagnostics (IVD) company specializing in point-of-care testing (POCT). Founded in 2018, the company leverages colloidal gold, fluorescence immunoassay, ELISA, chemiluminescence, and PCR technologies to develop diagnostic kits for infectious diseases, cardiac markers, inflammation, diabetes, hormones, and food safety. With a team of 50-200 employees, Reach Diagnostic operates in the commercial stage and has established a presence in the rapidly growing Chinese IVD market, particularly in POCT, which is expanding due to increasing demand for decentralized testing. The company's product portfolio addresses key health priorities, including hepatitis, respiratory infections, tropical diseases, and chronic conditions like diabetes and cardiovascular disease. By focusing on accessible and rapid diagnostic solutions, Reach Diagnostic is well-positioned to capture market share in China's evolving healthcare landscape. However, competition from established domestic and international players, along with regulatory complexities and potential pricing pressures, may limit near-term growth. The company's ability to innovate and secure regulatory approvals will be critical to its success.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for a novel POCT infectious disease panel70% success
• Q4 2026Strategic partnership with a major Chinese hospital group for distribution65% success
• Q1 2027Launch of a new chemiluminescence immunoassay platform for cardiac markers60% success